Amneal Pharmaceuticals In... (AMRX)
8.24
-0.03 (-0.30%)
At close: Mar 28, 2025, 12:37 PM
Amneal Pharmaceuticals Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
| Revenue | 2.79B | 2.39B | 2.21B | 2.09B | 1.99B | 1.63B | 1.66B | 1.03B | 1.02B | 866.28M | 785.62M |
| Cost of Revenue | 1.77B | 1.57B | 1.43B | 1.32B | 1.36B | 1.27B | 946.59M | 507.48M | 420.77M | 367.05M | 335.99M |
| Gross Profit | 1.02B | 820.57M | 784.71M | 768.97M | 628.39M | 353M | 716.4M | 526.18M | 597.46M | 499.23M | 449.63M |
| Operating Income | 249.33M | 204.37M | 206.46M | 209.24M | 91.16M | -137.42M | -19.67M | 245.1M | 284.88M | 227.23M | 222.94M |
| Interest Income | n/a | n/a | 158.38M | 136.32M | 146M | 168.21M | n/a | n/a | n/a | 45.84M | 30.66M |
| Pretax Income | -55.01M | -40.27M | -248.13M | 31.37M | -35.78M | -220.24M | -202.72M | 171.32M | 214.82M | 175.58M | 179.33M |
| Net Income | -116.89M | -83.99M | -254.79M | 20.17M | 68.58M | -603.57M | -169.73M | 167.65M | 207.38M | 169.45M | 176.93M |
| Selling & General & Admin | 476.44M | 429.68M | 399.7M | 365.5M | 326.73M | 289.6M | 230.44M | 109.05M | 118.76M | 109.68M | 84.61M |
| Research & Development | 196.56M | 167.78M | 200.05M | 209.56M | 190.59M | 202.29M | 210.45M | 191.94M | 204.75M | 136.87M | 106.73M |
| Other Expenses | 98.12M | 18.74M | -3.96M | 15.33M | 2.59M | 1.47M | 2.85M | -47K | -669K | n/a | n/a |
| Operating Expenses | 771.11M | 616.19M | 595.79M | 575.07M | 517.31M | 491.88M | 440.89M | 300.98M | 323.5M | 277.81M | 239.64M |
| Interest Expense | 258.6M | 210.63M | 158.38M | 136.32M | 146M | 168.21M | 143.57M | 71.06M | 55.28M | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 2.54B | 2.19B | 2.02B | 1.9B | 1.88B | 1.77B | 1.39B | 808.46M | 744.27M | 644.86M | 575.63M |
| Income Tax | 18.86M | 8.45M | 6.66M | 11.2M | -104.36M | 383.33M | -1.42M | 2M | 5.39M | 4.95M | 1.51M |
| Shares Outstanding (Basic) | 308.98M | 174.99M | 150.94M | 148.92M | 147.44M | 132.09M | 127.25M | 114.86M | 114.86M | 189M | n/a |
| Shares Outstanding (Diluted) | 308.98M | 176.14M | 150.94M | 151.82M | 148.91M | 132.11M | 127.25M | 114.86M | 114.86M | 189M | n/a |
| EPS (Basic) | -0.38 | -0.48 | -1.69 | 0.14 | 0.47 | -4.57 | -1.33 | 1.46 | 1.81 | 0.90 | n/a |
| EPS (Diluted) | -0.38 | -0.48 | -1.69 | 0.13 | 0.46 | -4.57 | -1.33 | 1.46 | 1.81 | 0.90 | n/a |
| EBITDA | 439.77M | 399.76M | 150.43M | 450M | 381.05M | 155.2M | -19.67M | 271.13M | 306.97M | 252.68M | 243.28M |
| Depreciation & Amortization | 236.19M | 229.4M | 240.18M | 233.41M | 235.39M | 207.24M | 137.4M | 45.94M | 33.02M | 25.45M | 20.34M |